Organon & Co. (NYSE:OGN) Announces $0.28 Quarterly Dividend

Organon & Co. (NYSE:OGN) announced a quarterly dividend on Thursday, May 2nd, Zacks reports. Investors of record on Monday, May 13th will be given a dividend of 0.28 per share on Thursday, June 13th. This represents a $1.12 dividend on an annualized basis and a yield of 5.50%. The ex-dividend date is Friday, May 10th.

Organon & Co. Trading Down 0.1 %

Shares of OGN opened at $20.37 on Thursday. The firm has a market capitalization of $5.24 billion, a P/E ratio of 4.98, a P/E/G ratio of 0.88 and a beta of 0.81. Organon & Co. has a 12-month low of $10.84 and a 12-month high of $24.08. The firm has a fifty day moving average price of $18.35 and a 200-day moving average price of $15.86.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, February 15th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.14. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a net margin of 16.50% and a negative return on equity of 259.73%. Analysts predict that Organon & Co. will post 4.1 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on OGN. The Goldman Sachs Group increased their target price on shares of Organon & Co. from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Piper Sandler boosted their price objective on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Monday, April 29th.

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, insider Kirke Weaver acquired 2,720 shares of the stock in a transaction dated Thursday, February 22nd. The stock was purchased at an average price of $18.36 per share, with a total value of $49,939.20. Following the transaction, the insider now directly owns 15,181 shares of the company’s stock, valued at $278,723.16. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.17% of the stock is owned by insiders.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.